{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzltsp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzltsp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/49\\\/13\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/49\\\/13\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/49\\\/13\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/49\\\/13\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003ERenin-angiotensin-aldosterone system inhibitors (RAASis) are beneficial and recommended for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, hyperkalemia (HK) often limits RAASi therapy. The OPAL-HK [\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT01810939\u0026amp;atom=%2Fspmdc%2F14%2F49%2F13.atom\u0022\u003ENCT01810939\u003C\/a\u003E] trial found that patiromer normalized serum potassium (s-K+) and prevent HK recurrence compared with placebo. This article discusses a poster investigating the prespecified analysis of the subgroup with T2DM in OPAL-HK.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EDiabetes \u0026amp; Kidney Disease Renal Insufficiency\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENephrology Clinical Trials\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EDiabetes Mellitus\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EDiabetes \u0026amp; Kidney Disease\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENephrology\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ERenal Insufficiency\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENephrology Clinical Trials\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EDiabetes Mellitus\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \n         \u003Cp id=\u0022p-2\u0022\u003ERenin-angiotensin-aldosterone system inhibitors (RAASis) are beneficial and recommended for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) [ADA. \u003Cem\u003EDiabetes Care\u003C\/em\u003E. 2014]. However, hyperkalemia (HK) often limits RAASi therapy [Einhorn LM et al. \u003Cem\u003EArch Intern Med.\u003C\/em\u003E 2009]. Current treatment options for chronic management of HK are limited [Fordjour KN et al. \u003Cem\u003EAm J Med Sci.\u003C\/em\u003E 2014; Harel Z et al. \u003Cem\u003EAm J Med.\u003C\/em\u003E 2013], and an unmet need remains for safe and effective HK treatment.\u003C\/p\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EPatiromer has previously been shown to normalize serum potassium (s-K\u003Csup\u003E+\u003C\/sup\u003E) and prevent HK recurrence compared with placebo in A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia [OPAL-HK; \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT01810939\u0026amp;atom=%2Fspmdc%2F14%2F49%2F13.atom\u0022\u003ENCT01810939\u003C\/a\u003E]. Matthew R. Weir, MD, University of Maryland, Baltimore, Maryland, USA, presented poster FR-PO792, which described the prespecified analysis of the subgroup with T2DM in OPAL-HK.\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EIn part A (4-week treatment phase), patients with CKD with and without T2DM on stable doses of \u2265 1 RAASi with mild HK (s-K\u003Csup\u003E+\u003C\/sup\u003E 5.1 to \u0026lt; 5.5 mEq\/L; n = 92) received patiromer 4.2 g BID; those with moderate-to-severe HK (s-K\u003Csup\u003E+\u003C\/sup\u003E 5.5 to \u0026lt; 6.5 mEq\/L; n = 151) received patiromer 8.4 g BID. After 4 weeks, patients with moderate-to-severe HK continued on to the 8-week withdrawal phase (part B) and were randomly assigned to patiromer plus RAASi (n = 55) or placebo plus RAASi (n = 52).\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EEnd points included change in s-K\u003Csup\u003E+\u003C\/sup\u003E from baseline to week 4, percentage of patients with s-K\u003Csup\u003E+\u003C\/sup\u003E within target at week 4, between-group difference in s-K\u003Csup\u003E+\u003C\/sup\u003E change over the first 4 weeks, and percentage of patients with recurrent HK.\u003C\/p\u003E\n         \u003Cp id=\u0022p-6\u0022\u003ET2DM was present in 138 (57%) of patients assessed for the primary end point. The mean change from baseline to week 4 for patients with T2DM was \u22121.00 \u00b1 0.04 (95% CI, \u22121.08 to \u22120.92; \u003Cem\u003EP\u003C\/em\u003E \u0026lt; .001); for those without T2DM it was \u22121.02 \u00b1 0.05 (95% CI, \u22121.12 to \u22120.92; \u003Cem\u003EP\u003C\/em\u003E \u0026lt; .001); (\u003Cem\u003EP\u003C\/em\u003E = .77 for interaction). In a secondary end point, 78% and 73% of patients with and without T2DM, respectively, had s-K\u003Csup\u003E+\u003C\/sup\u003E within range at week 4.\u003C\/p\u003E\n         \u003Cp id=\u0022p-7\u0022\u003EThe median increase in s-K\u003Csup\u003E+\u003C\/sup\u003E from baseline at week 4 of the withdrawal phase was larger for the placebo group (n = 33; 0.69 mEq\/L; 95% CI, 0.19 to 1.29) than for the patiromer group (n = 34; 0.03 mEq\/L; 95% CI, \u22120.20 to 0.30; \u003Cem\u003EP\u003C\/em\u003E \u0026lt; .001) in patients with T2DM (\u003Cem\u003EP\u003C\/em\u003E \u0026lt; .001).\u003C\/p\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EPatiromer increased the time to first recurrent HK event vs placebo in patients with T2DM. Through week 8 of the withdrawal phase, significantly (\u003Cem\u003EP\u003C\/em\u003E \u0026lt; .001) more T2DM patients on placebo (62%) vs patiromer (19%) had at least 1 recurrent HK event.\u003C\/p\u003E\n         \u003Cp id=\u0022p-9\u0022\u003EPatiromer was well tolerated in patients with T2DM, with mild-to-moderate constipation being the most common adverse event (13% in Part A, 6% in Part B).\u003C\/p\u003E\n         \u003Cp id=\u0022p-10\u0022\u003EFor patients with CKD, T2DM, and HK who are taking RAASis, patiromer may provide an option for HK management.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/49\/13.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzltsp\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}